Journal Full Title: Journal of Biomedical Research & Environmental Sciences


Journal Website Link: https://www.jelsciences.com

Journal ISSN: 2766-2276

Category: Multidisciplinary

Subject Areas: Medicine Group, Biology Group, General, Environmental Sciences

Topics Summation: 128

Issue Regularity: Monthly

Review Process type: Double Blind

Time to Publication: 7-14 Days

Indexing catalog: Visit here

Publication fee catalog: Visit here

DOI: 10.37871 (CrossRef)

Plagiarism detection software: iThenticate

Managing entity: USA

Language: English

Research work collecting capability: Worldwide

Organized by: SciRes Literature LLC

License: Open Access by Journal of Biomedical Research & Environmental Sciences is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at SciRes Literature LLC.

Manuscript should be submitted in Word Document (.doc or .docx) through Online Submission form or can be mailed to support@jelsciences.com

Vision

Journal of Biomedical Research & Environmental Sciences main aim is to enhance the importance of science and technology to the scientific community and also to provide an equal opportunity to seek and share ideas to all our researchers and scientists without any barriers to develop their career and helping in their development of discovering the world.
BRIEF REPORT

Importance the Type 1 (CR1) and Type 3 (CR3) Complement Receptors in the Infectious Disease

Cassio Marinho Campelo*
Federal University of Ceará, Biomedicine Center, Laboratory of Medical Immunology, Brazil

The complement system is one of the host’s primary defence mechanisms against pathogens. Its activation involves proteolytic cascades of enzymatic reactions that result in products with effector functions and recognition of molecules on the surface of microorganisms [1,2].

Complement activation depends on a proteolytic cascade of enzymatic reactions that result in products with effects function of molecules identification in microorganism surface for complement classical, alternative, and lectin pathways, converging to C3 complement central protein and formation of subproducts C3a and C3b [1,2].

The C3a subunit is a small fragment complement protein that promotes inflammation. The C3b subunit is an opsonin potent covalently binds to the microorganisms’ surface, signaling mononuclear phagocytes recruitment, promoting the phagocytose, and activating the three complement pathways, and forms a Membrane Attack Complex (MAC) [1,2].

The complement receptors are cell–surface G Protein-Coupled Receptors (GPCRs) with distribution in innate and adaptative immune system cells. It binds for opsonized microorganisms facilitating recognition, capture, and internalization by the mononuclear phagocyte. They are structurally different [2,3].

Complement Receptor type 1 (CR1) is a polymorphic glycoprotein of the only chain, with 30 Complement Control Protein domains (CCPs), two interaction sites with high affinity to C3b and C4b complement subunit, responsible for decay C3 and C5 convertase, strong binding with C4b and higher binding with C3b [2,4].

CR1 is present on the surface of erythrocytes, monocytes, neutrophils, macrophages, lymphocytes. CR1 acts to regulate the complement cascade as a receptor for C3b and C4b subunit; he promotes the clearance of immune complex binding in erythrocyte surfaces; it is a receptor essential in the phagocytosis process for monocytes and neutrophils in inflammation, and it regulates the B lymphocytes between T lymphocytes response [2,4].

In autoimmune diseases and other inflammatory disorders, the CR1 expression modulates autoantibodies that cause accumulation of complex immune. While CR1 polymorphism in infectious disease has a consequence in the resistance Plasmodium falciparum infection in malaria and susceptibility HIV, increase viral replication in monocytes and lymphocyte T CD4 [5–9].
The modulation of expression CR1 in disease involves mechanisms with a difference in cytokine production for leucocytes, variation in the immune response, and changes in the inflammatory conditions of systemic form [2,4].

The Complement Receptor type 3 (CR3), also called Mac-1 and αMβ2, belong to the integrins family with different subunits with high binding to inactive complement fragment iC3b. CR3 is express in neutrophils, monocytes, macrophages, granulocytes, and NK cells. CR3 involves phagocytoses, adhesion cells, oxidative burst, leukocytes movement, and regulated inflammation process [2,4].

When a microorganism infects a host occur activation of phagocytic cells, migration cell process mediated for CR3. Phagocytic cells make capture and internalization of microorganisms used surface receptors. CR3 recognizes the opsonized pathogens by fragments C3 (C3b and iC3b), stimulating increased phagocytosis. The phagocytosis process decreased the complement receptor on the cell surface [2,4].

In leishmaniasis, the parasite uses the GP63 express in your membrane to cleavage fragment C3b to a fragment iC3b, destroying almost all your binding sites present on C3b, and promoting increased adhesion cell in monocytes, neutrophils, and macrophages. The CR1 and CR3 expression modulation has a critical role in visceral leishmaniasis, causing severe clinical presentation [10].

The CR1 and CR3 complement receptors can be a biomarker to future research as targets to new drugs and understand pathogenesis in the infectious disease.

References


How to cite this article: Campelo CM. Importance the Type 1 (CR1) and Type 3 (CR3) Complement Receptors in the Infectious Disease. J Biomed Res Environ Sci. 2021 Mar 31; 2(3): 216-217. doi: 10.37871/jbres1214, Article ID: JBRES1214